Rash & Diarrhea Prophylaxis With Capivasertib
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a randomized, multicenter, phase II clinical trial evaluating prophylactic strategies to mitigate common toxicities associated with capivasertib in combination with fulvestrant in participants with hormone receptor-positive (HR+), HER2-negative advanced breast cancer who are eligible for this treatment regimen.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent musi mieć ukończone 18 lat i być w stanie wyrazić świadomą zgodę na udział w badaniu.
- •Pacjent musi mieć zaawansowanego raka piersi, który rozprzestrzenił się lub nie daje się wyleczyć operacyjnie.
- •Rak piersi musi mieć specyficzne zmiany genetyczne (w genach PIK3CA/AKT1/PTEN).
- •Pacjent kwalifikuje się do leczenia kapiwasertybem i fulwestrantem.
- •Pacjent ma dobry ogólny stan zdrowia, pozwalający na udział w badaniu.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Yale University
New Haven, United States
Trial contact
Laura Kane
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/31/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.